Akebia was founded in 2007 when the company in-licensed three preclinical programs from Procter & Gamble Pharmaceuticals (P&G):
- a HIF2 stabilizer program
- a HIFI stabilizer program
- a Tie 2 activator program
In late 2011, the Tie 2 activator program and the HIFI stabilizer program were spun off into a separate company, Aerpio Therapeutics.
Akebia has an experienced development team that works closely with a network of world-renowned consultants and advisors. Based on data from studies conducted by P&G and additional preclinical and clinical work performed by Akebia, Akebia is focusing on developing the HIF2 stabilizer program:
• AKB-6548 (HIF-PH inhibitor) is the lead compound in the HIF2 stabilizer program and is currently in a phase 2b clinical trial for anemia related to chronic kidney disease. AKB-6548 promises to offer many advantages over products currently used to treat anemia, including an improved safety profile, oral dosing and lower costs.